NASDAQ:MNPR Monopar Therapeutics Q3 2026 Earnings Date & Estimates $71.91 -1.48 (-2.02%) Closing price 04:00 PM EasternExtended Trading$71.97 +0.06 (+0.09%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Monopar Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 10, 2026 at 12:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeBefore Market OpensConference Call DateNovember 10, 2026Conference Call12:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Monopar Therapeutics in Q3 2026Monopar Therapeutics is expected to post earnings of -$0.86 per share. In the same quarter a year earlier Monopar Therapeutics reported -$0.48 per share. Monopar Therapeutics last reported on August 12, 2026, posting -$0.62 per share and beating the -$0.6425 consensus estimate. Monopar Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.86Prior-Year EPS-$0.48Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.62 (Beat by +$0.0225)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Monopar Therapeutics Q3 2026 Earnings FAQ When does Monopar Therapeutics report Q3 2026 earnings? Monopar Therapeutics (NASDAQ:MNPR) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Monopar Therapeutics' Q3 2026 earnings call? Monopar Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Monopar Therapeutics? Analysts expect Monopar Therapeutics to post earnings of -$0.86 per share for Q3 2026. Monopar Therapeutics Earnings HeadlinesMonopar Therapeutics Insider Sold Shares Worth $659,387, According to a Recent SEC FilingOctober 5, 2026 | marketscreener.comMPiper Sandler Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR)September 29, 2026 | theglobeandmail.comThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former hedge fund trader Lance Ippolito says it identifies early moves and lets traders set their own risk level instead of guessing.October 29 at 1:00 AM | The TradingPub (Ad)Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026August 19, 2026 | markets.businessinsider.comMonopar Appoints Jeffrey D. Kent, M.D.August 19, 2026 | globenewswire.comMonopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'August 18, 2026 | seekingalpha.comSee More Monopar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monopar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monopar Therapeutics and other key companies, straight to your email. Email Address About Monopar TherapeuticsMonopar Therapeutics (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies. Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR. The company is also developing related uPAR-targeted radiopharmaceutical programs, including MNPR-101-Lu, which is designed to deliver targeted radiation to cancer cells. Monopar has also pursued camsirubicin, an investigational anthracycline designed to retain anticancer activity while potentially reducing the heart-related toxicity associated with conventional anthracyclines. The company is headquartered in the United States and conducts its programs through clinical development and collaborations. Ian W. Ratner is the company’s co-founder and chief executive officer.View Monopar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Colgate-Palmolive (10/30/2026)BP (10/30/2026)Chevron (10/30/2026)ExxonMobil (10/30/2026)NatWest Group (10/30/2026)AbbVie (10/30/2026)AstraZeneca (10/30/2026)Regeneron Pharmaceuticals (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
